Rhumbline Advisers increased its holdings in shares of C.R. Bard, Inc. (NYSE:BCR) by 1.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 150,150 shares of the medical instruments supplier’s stock after buying an additional 2,275 shares during the quarter. Rhumbline Advisers owned 0.21% of C.R. Bard worth $48,123,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also modified their holdings of the company. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its stake in C.R. Bard by 70.4% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock valued at $145,000 after purchasing an additional 190 shares in the last quarter. Parallel Advisors LLC grew its stake in C.R. Bard by 2.8% in the second quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock valued at $164,000 after purchasing an additional 14 shares in the last quarter. Captrust Financial Advisors purchased a new position in C.R. Bard in the second quarter valued at about $192,000. Choate Investment Advisors purchased a new position in C.R. Bard in the second quarter valued at about $201,000. Finally, Argyle Capital Management Inc. purchased a new position in C.R. Bard in the second quarter valued at about $209,000. Institutional investors and hedge funds own 78.27% of the company’s stock.
BCR has been the topic of a number of recent research reports. Zacks Investment Research upgraded C.R. Bard from a “hold” rating to a “buy” rating and set a $360.00 target price on the stock in a research note on Monday, July 31st. Jefferies Group LLC restated a “hold” rating on shares of C.R. Bard in a research note on Thursday, August 3rd. BidaskClub downgraded C.R. Bard from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Barclays PLC boosted their target price on C.R. Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a research note on Monday, November 6th. Finally, Needham & Company LLC restated a “hold” rating on shares of C.R. Bard in a research note on Thursday, October 26th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a strong buy rating to the stock. C.R. Bard presently has a consensus rating of “Hold” and a consensus target price of $303.50.
Shares of C.R. Bard, Inc. (NYSE BCR) traded up $0.26 during trading hours on Wednesday, hitting $333.34. The company’s stock had a trading volume of 260,200 shares, compared to its average volume of 666,717. C.R. Bard, Inc. has a 12 month low of $203.77 and a 12 month high of $335.84. The firm has a market capitalization of $24,300.00, a PE ratio of 28.76, a P/E/G ratio of 2.55 and a beta of 0.53. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.57.
C.R. Bard (NYSE:BCR) last announced its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.96 by $0.06. C.R. Bard had a return on equity of 48.28% and a net margin of 14.75%. The company had revenue of $989.80 million during the quarter, compared to analysts’ expectations of $990.64 million. During the same quarter in the previous year, the firm earned $2.64 earnings per share. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. equities analysts forecast that C.R. Bard, Inc. will post 11.89 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be given a dividend of $0.26 per share. The ex-dividend date of this dividend is Thursday, December 7th. This represents a $1.04 annualized dividend and a dividend yield of 0.31%. C.R. Bard’s dividend payout ratio is presently 13.70%.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.